Skip to search formSkip to main contentSkip to account menu

NK 313

Known as: NK313 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
SummaryLiblomycin (NK313) is a bleomycin analog that has proved to be associated with less pulmonary toxicity and with more… 
1992
1992
To determine the optimal administration schedules of the newly synthesized, less nephrotoxic platinum analog NK121 and less… 
1991
1991
Liblomycin (NK313) is a novel derivative of bleomycin (BLM) and peplomycin (PEP). The cell kill kinetics of NK313 on rat ascites… 
1991
1991
In order to exploit the optimal administration schedules of newly synthesized analogues of cisplatin (NK121) and bleomycin (NK313… 
1990
1990
ヌードマウス可移植性ヒト悪性黒色腫 (SK-14株) に対するLiblomycin (NK313) とPeplomycin (PEP) の単独投与した成績を比較検討した。その結果, NK313およびPEP… 
Highly Cited
1989
Highly Cited
1989
A new model to predict antitumor activity of new analogues was developed, and the cross-resistance against cisplatin (CDDP) and… 
1988
1988
Liblomycin (NK313), a novel analog of bleomycin and peplomycin (PEP), produced acid soluble DNA, base propenals and nucleo bases…